FDA Approves Ilumya for Adults With Active Psoriatic Arthritis

The FDA has approved Ilumya (tildrakizumab) for treating adults with active psoriatic arthritis, expanding its use beyond moderate-to-severe plaque psoriasis. The approval is based on clinical trials showing significant symptom improvement and manageable safety profile.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.